F-star Therapeutics (NASDAQ:FSTX - Get Rating) was downgraded by equities researchers at SVB Leerink from an "outperform" rating to a "market perform" rating in a research note issued to investors on Thursday, The Fly reports.
FSTX has been the subject of a number of other reports. HC Wainwright initiated coverage on F-star Therapeutics in a research note on Tuesday, May 17th. They set a "buy" rating and a $35.00 price objective for the company. LADENBURG THALM/SH SH cut F-star Therapeutics from a "buy" rating to a "neutral" rating in a research note on Thursday. Laidlaw cut F-star Therapeutics from a "buy" rating to a "hold" rating in a research note on Thursday. Finally, William Blair cut F-star Therapeutics from an "outperform" rating to a "market perform" rating in a research note on Thursday. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $29.50.
Shares of FSTX stock traded up $0.03 on Thursday, reaching $6.39. 1,220,888 shares of the stock were exchanged, compared to its average volume of 207,453. F-star Therapeutics has a one year low of $2.07 and a one year high of $9.30. The company has a current ratio of 6.11, a quick ratio of 6.11 and a debt-to-equity ratio of 0.14. The stock has a 50 day moving average price of $3.04 and a 200 day moving average price of $3.64.
F-star Therapeutics (NASDAQ:FSTX - Get Rating) last announced its quarterly earnings data on Tuesday, May 10th. The company reported ($0.57) EPS for the quarter, topping analysts' consensus estimates of ($0.63) by $0.06. The company had revenue of $2.55 million for the quarter, compared to analyst estimates of $2.30 million. As a group, equities research analysts expect that F-star Therapeutics will post -2.35 EPS for the current year.
Large investors have recently bought and sold shares of the business. Envestnet Asset Management Inc. acquired a new position in F-star Therapeutics in the first quarter valued at about $48,000. JPMorgan Chase & Co. boosted its position in shares of F-star Therapeutics by 152.7% during the first quarter. JPMorgan Chase & Co. now owns 21,335 shares of the company's stock worth $76,000 after buying an additional 12,891 shares during the period. Goldman Sachs Group Inc. acquired a new position in shares of F-star Therapeutics during the first quarter worth about $120,000. State Street Corp grew its holdings in shares of F-star Therapeutics by 15.6% during the first quarter. State Street Corp now owns 53,150 shares of the company's stock worth $189,000 after buying an additional 7,180 shares in the last quarter. Finally, BlackRock Inc. raised its position in F-star Therapeutics by 1.6% in the 1st quarter. BlackRock Inc. now owns 295,947 shares of the company's stock valued at $1,050,000 after buying an additional 4,776 shares during the last quarter. 51.67% of the stock is owned by hedge funds and other institutional investors.
About F-star Therapeutics (Get Rating)
F-star Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients.
Before you consider F-star Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and F-star Therapeutics wasn't on the list.
While F-star Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The 5 Stocks Here